Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

12-month supply and annual maintenance cost. 4.2.17 The Assessment Group used the same unit costs as used in NICE's technology appraisal guidance on clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events, updated to 2012 prices using the Hospital and Community Health Services inflation index. The unit cost of a fatal myocardial infarction is £2,373.68 (standard error £121.11, 95% CI £2,136.31 to £2,611.05), a non-fatal myocardial infarction is £6,165.21 (standard error £314.55, 95% CI £5,548.69 to £6,781.73), a fatal stroke is £9381.43 (standard error £478.64, 95% CI £8,443.29 to £10,319.57), a non-fatal non-disabling stroke is £6,858.64 (standard error £349.93, 95% CI £6,172.77 to £7,544.50), a non-fatal disabling stroke is £14,602.70 (standard error £754.04, 95% CI £13,142.43 to £16,062.97), and a non-vascular or other vascular death is £2,407.50 (standard error £122.83, 95% CI £2,166.75 to £2,648.25). The annual cost in the event-free or myocardial infarction-only health state is £618.03 (standard error £31.53, 95% CI £556.23 to £679.84). In the non-disabling stroke health state it is £1,804.06 (standard error £92.04, 95% CI £1,623.66 to £1,984.47) and in the disabling stroke health state it is £5,537.72 (standard error £282.54, 95% CI £4,983.95 to £6,091.50). 4.2.18 The Assessment Group obtained the continuing
